Acebutolol Side Effects & Health Impacts

CoQ10 deficiency can present in infancy as a severe encephalomyopathy or multisystemic mitochondrial disease, with features such as hypotonia, developmental delay, intractable seizures, lactic acidosis, cardiomyopathy, and failure to thrive. Reports of infantile‑onset multisystem CoQ10 deficiency describe very early presentations, sometimes in the neonatal period, with rapid neurologic deterioration and involvement of brain, heart, kidney, and liver, and many affected children die in the first months or years of life despite intensive care. The important clinical point is that, although outcomes are often poor in the most severe cases, some infants and young children show neurologic improvement or stabilization when CoQ10 deficiency is recognized early and high‑dose CoQ10 supplementation is started promptly, which is why this diagnosis is considered a treatable cause of infantile encephalomyopathy

Research: Quinzii CM, Hirano M. Coenzyme Q and mitochondrial disease. Dev Disabil Res Rev. 2010;16(2):183-8. Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol. 1997;37(4):212-8. Boitier E, Degoul F, Desguerre I, Charpentier C, François D, Ponsot G, Diry M, Rustin P, Marsac C. A case of mitochondrial encephalomyopathy associated with a muscle coenzyme Q10 deficiency. J Neurol Sci. 1998;156(1):41-6. Sobreira C, Hirano M, Shanske S, Keller RK, Haller RG, Davidson E, Santorelli FM, Miranda AF, Bonilla E, Mojon DS, Barreira AA, King MP, DiMauro S. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. Neurology. 1997 May;48(5):1238-43.

CoQ10 is a key mitochondrial antioxidant, and circulating levels are often reduced in people with chronic kidney disease and chronic heart failure, where deficiency is linked to greater oxidative stress and poorer organ function. In CKD cohorts, lower CoQ10 levels correlate with increased cardiovascular risk, and supplementation has been reported to improve markers such as proteinuria, mitochondrial function, and oxidative stress, with some studies suggesting better preservation of kidney function over time. In patients with chronic heart failure, trials such as Q-SYMBIO have shown that CoQ10 supplementation can improve cardiac function parameters and significantly reduce major adverse cardiovascular events, cardiovascular mortality, and heart‑failure–related hospitalizations.

Research: Xu Y, Liu J, Han E, Wang Y, Gao J. Efficacy of coenzyme Q10 in patients with chronic kidney disease: protocol for a systematic review. BMJ Open. 2019 May 14;9(5):e029053. Bakhshayeshkaram M, Lankarani KB, Mirhosseini N, Tabrizi R, Akbari M, Dabbaghmanesh MH, Asemi Z. The Effects of Coenzyme Q10 Supplementation on Metabolic Profiles of Patients with Chronic Kidney Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Curr Pharm Des. 2018;24(31):3710-3723. Di Lorenzo A, Iannuzzo G, Parlato A, Cuomo G, Testa C, Coppola M, D'Ambrosio G, Oliviero DA, Sarullo S, Vitale G, Nugara C, Sarullo FM, Giallauria F. Clinical Evidence for Q10 Coenzyme Supplementation in Heart Failure: From Energetics to Functional Improvement. J Clin Med. 2020 Apr 27;9(5):1266. DiNicolantonio JJ, Bhutani J, McCarty MF, O'Keefe JH. Coenzyme Q10 for the treatment of heart failure: a review of the literature. Open Heart. 2015;2:e000326.

CoQ10 deficiency has been identified as a potentially reversible cause of steroid‑resistant nephrotic syndrome and glomerular nephropathy, particularly in children and young adults with genetic defects in CoQ10 biosynthesis. In reported series, affected patients often present with heavy proteinuria and progressive kidney dysfunction that fail to respond to standard steroid therapy, but genetic testing sometimes reveals mutations in CoQ10‑related genes (such as COQ2, COQ6, or ADCK4). The encouraging part is that in a subset of these cases, early and sufficiently dosed CoQ10 supplementation has been associated with reduced proteinuria and stabilization or partial improvement of kidney function, making it an important, treatable consideration in otherwise unexplained steroid‑resistant nephrotic syndrome.

Research: Frehat MQ Sr, Alhadidi A, Almheairat A, Alkhatib L, Al Thaher S, Al Assaf R, Al Qawaqenah M, Mansour B, Khair F. Success of Coenzyme Q10 in Treating Steroid-Resistant Nephrotic Syndrome in Jordan: A Case Series. Cureus. 2025 Apr 30;17(4):e83231. Drovandi S, Lipska-Ziętkiewicz BS, Ozaltin F, et al. Oral Coenzyme Q10 supplementation leads to better preservation of kidney function in steroid-resistant nephrotic syndrome due to primary Coenzyme Q10 deficiency. Kidney Int. 2022 Sep;102(3):604-612. Drovandi S, Lipska-Ziętkiewicz BS, et al. Variation of the clinical spectrum and genotype-phenotype associations in Coenzyme Q10 deficiency associated glomerulopathy. Kidney Int. 2022 Sep;102(3):592-603. Salviati L, Sacconi S, Murer L, Zacchello G, Franceschini L, Laverda AM, Basso G, Quinzii C, Angelini C, Hirano M, Naini AB, Navas P, DiMauro S, Montini G. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology. 2005 Aug 23;65(4):606-8.

In some children and young adults, primary CoQ10 deficiency has been linked to hypertrophic cardiomyopathy (HCM), where the heart muscle becomes abnormally thick and stiff despite the absence of more common causes like longstanding hypertension. Case series and reports describe patients with genetically confirmed CoQ10 biosynthetic defects who develop HCM alongside other mitochondrial features such as exercise intolerance, muscle weakness, or neurologic symptoms, and cardiac imaging often shows concentric or asymmetric left ventricular hypertrophy. The hopeful aspect is that early recognition and CoQ10 supplementation have, in some documented cases, led to improved cardiac function or stabilization of wall thickness over time, making CoQ10 deficiency a particularly important and potentially treatable consideration in otherwise unexplained or familial‑appearing HCM.

Research: Adarsh K, Kaur H, Mohan V. Coenzyme Q10 (CoQ10) in isolated diastolic heart failure in hypertrophic cardiomyopathy (HCM). Biofactors. 2008;32(1-4):145-9. Sharma A, Fonarow GC, Butler J, Ezekowitz JA, Felker GM. Coenzyme Q10 and Heart Failure: A State-of-the-Art Review. Circ Heart Fail. 2016 Apr;9(4):e002639. Sondheimer N, Hewson S, Cameron JM, Somers GR, Broadbent JD, Ziosi M, Quinzii CM, Naini AB. Novel recessive mutations in COQ4 cause severe infantile cardiomyopathy and encephalopathy associated with CoQ10 deficiency. Mol Genet Metab Rep. 2017 May 11;12:23-27. Smet J, De Meirleir L. Early myoclonic epilepsy, hypertrophic cardiomyopathy and subsequently a nephrotic syndrome in a patient with CoQ10 deficiency caused by mutations in para-hydroxybenzoate-polyprenyl transferase (COQ2). Eur J Paediatr Neurol. 2013 Nov;17(6):625-30.

CoQ10 deficiency is a recognized cause of progressive cerebellar ataxia with cerebellar atrophy, often beginning in childhood or early adulthood and frequently accompanied by seizures, peripheral neuropathy, and cognitive or psychiatric changes. Case series and larger cohorts show that many patients with primary CoQ10 deficiency have prominent cerebellar atrophy on MRI and mixed neurologic features, and in some reports seizures occurred in roughly one‑third of affected individuals. The hopeful aspect is that, unlike many hereditary ataxias, early and sustained CoQ10 supplementation has led to meaningful improvement or stabilization of gait, strength, and seizure control in a substantial subset of patients, which is why CoQ10 deficiency is emphasized as a treatable cause of cerebellar ataxia that should not be missed.

Research: Lamperti C, Naini A, Hirano M, De Vivo DC, Bertini E, Servidei S, Valeriani M, Lynch D, Banwell B, Berg M, Dubrovsky T, Chiriboga C, Angelini C, Pegoraro E, DiMauro S. Cerebellar ataxia and coenzyme Q10 deficiency. Neurology. 2003 Apr 8;60(7):1206-8. Artuch R, Brea-Calvo G, Briones P, Aracil A, Galván M, Espinós C, Corral J, Volpini V, Ribes A, Andreu AL, Palau F, Sánchez-Alcázar JA, Navas P, Pineda M. Cerebellar ataxia with coenzyme Q10 deficiency: diagnosis and follow-up after coenzyme Q10 supplementation. J Neurol Sci. 2006 Jul 15;246(1-2):153-8. Hirano M, Quinzii C, DiMauro S. Restoring balance to ataxia with coenzyme Q10 deficiency. Journal of the Neurological Sciences, 246, 11-12. Naini A, Lewis VJ, Hirano M, DiMauro S. Primary coenzyme Q10 deficiency and the brain. Biofactors. 2003;18(1-4):145-52.

In some adolescents and adults, CoQ10 deficiency presents as an isolated mitochondrial myopathy with exercise intolerance, early fatigue, and proximal muscle weakness rather than a full multisystem syndrome. Muscle biopsies in these patients often show reduced CoQ10 content and ragged‑red fibers or other mitochondrial changes, even when brain, heart, and kidneys appear largely spared on standard evaluation. The encouraging piece is that many individuals with CoQ10‑deficient myopathy experience noticeable improvements in exercise capacity, muscle strength, and CK levels after several months of adequately dosed CoQ10 supplementation, highlighting the importance of recognizing this treatable cause of mitochondrial muscle disease early.

Research: Lalani SR, Vladutiu GD, Plunkett K, Lotze TE, Adesina AM, Scaglia F. Isolated Mitochondrial Myopathy Associated With Muscle Coenzyme Q10 Deficiency. Arch Neurol. 2005;62(2):317–320. Neergheen V, Chalasani A, Wainwright L, et al. Coenzyme Q10 in the Treatment of Mitochondrial Disease. Journal of Inborn Errors of Metabolism and Screening. 2017;5Sacconi S, Trevisson E, Salviati L, Aymé S, Rigal O, Redondo AG, Mancuso M, Siciliano G, Tonin P, Angelini C, Auré K, Lombès A, Desnuelle C. Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscul Disord. 2010 Jan;20(1):44-8. Quinzii CM, Hirano M. Coenzyme Q and mitochondrial disease. Dev Disabil Res Rev. 2010;16(2):183-8.

In the gums and supporting tissues around the teeth, low CoQ10 levels have been linked to worse periodontal inflammation and deeper pocketing, likely because CoQ10 is essential for local mitochondrial energy production and antioxidant defense. Small human studies have found that people with periodontitis often have reduced CoQ10 in gingival tissue or crevicular fluid, and that topical or oral CoQ10 used alongside standard scaling and root planing can modestly improve measures such as bleeding on probing and pocket depth. The practical implication is that maintaining adequate CoQ10 status may help support healthier periodontal tissues and could be a useful adjunctive strategy, particularly in individuals with chronic gum disease or high oxidative stress in the oral cavity.

Research: Prakash S, Sunitha J, Hans M. Role of coenzyme Q(10) as an antioxidant and bioenergizer in periodontal diseases. Indian J Pharmacol. 2010 Dec;42(6):334-7. R. Nakamura, G.P. Littarru, K. Folkers, & E.G. Wilkinson. Study of CoQ10-Enzymes in Gingiva from Patients with Periodontal Disease and Evidence for a Deficiency of Coenzyme Q10*, Proc. Natl. Acad. Sci. U.S.A. 71 (4) 1456-1460. Ali K. Barakat et.al. Clinical Evaluation of Co-enzyme Q10 in Management of Chronic Periodontitis Patients: Mouth Split Study. International Journal of Health Sciences & Research. Vol.9; Issue: 1; January 2019.